Tumor mutational burden (TMB) is a genomic biomarker. In contrast to other biomarkers that are detected as a genomic alteration in a specific gene or via methods like immunohistochemistry, TMB is calculated. However, disagreements about calculation method, clinical indication for immunotherapy, and other factors have hindered establishment of TMB as a standardized biomarker.

The MH Guide software supports therapy decisions in oncology. It can translate data obtained from molecular tumor diagnostic tests into clinically relevant knowledge. This overview illustrates the practical use of the MH Guide.

NGS, WGS, SNV – What do these abbreviations stand for in molecular pathological diagnostics? What are the benefits of NGS-based panel diagnostics in oncology? This overview provides answers regarding methods of molecular tumor diagnostic testing.

After several therapies and relapses, a 70-year-old female patient with advanced ovarian cancer experienced renewed progression. The use of Molecular Health Guide (MH Guide) provided the molecular tumor board with comprehensive insights and individual therapeutic recommendations.

Tailor-made cancer treatments based on molecular target structures – that’s the premise of personalized tumor therapy. Software-supported solutions like MH Guide can help pinpoint addressable biomarkers as well as treatment options. Read on for answers to the most common questions about MH Guide.